Ivan Hyep

Ivan Hyep

M.B.A Chief Financial OfficeratBicara Therapeutics· In proxies 2023–2024

Pay in FY2024+45% from the year before

Ivan Hyep was paid $3.6M in FY2024 (Dec), up 45%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each Bicara Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Bicara TherapeuticsPublic company · 3 yr
    • M.B.A Chief Financial Officer2023 – Present · 3 yrStock in role -58%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?